PDCD1 and non-small cell lung carcinoma: Currently, it is approved in monotherapy or combination with nivolumab, an anti-PD-1 antibody, in multiple settings (e.g., melanoma, NSCLC, renal cell carcinoma, colorectal carcinoma with Mismatch Repair Deficiency (dMMR) or Microsatellite Instability-High (MSI-H), and others) [28,39].